Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MCK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMcKesson raises FY2027 guidance on 20% Q1 adjusted EPS growth, boosts dividend 15%
Filed August 5, 2026 · Period ending August 5, 2026 · ~1 min read
Key Changes
-
high
Q1 FY2027 adjusted EPS rose 20% to $9.93; full-year guidance raised to $44.20–$45.00 (from $43.80–$44.60), implying 13%–15% growth. Revenues up 8% to $105.4 billion on higher prescription volumes and specialty distribution.
Item 2.02 verify on EDGAR → -
high
Board approved 15% dividend increase to $0.94/share (from $0.82), marking tenth consecutive year of increases. Returned $2.6 billion to shareholders in Q1, including $2.5 billion in buybacks.
Item 2.02 verify on EDGAR → -
high
Medical-Surgical Solutions separation advanced: sold ~13% stake to Apollo for $1.25 billion (June 1), established $2.25 billion Term Loan B (June 9), unveiled Wellverse as standalone business name (August 5).
Item 2.02 verify on EDGAR → -
medium
GAAP diluted EPS fell to $5.15 from $6.25 prior year, primarily due to $293 million redemption value adjustment on redeemable noncontrolling interests in Medical-Surgical Solutions segment.
Item 2.02 verify on EDGAR → -
medium
Thomas L. Rodgers retired as EVP, Chief Strategy and Business Development Officer (effective August 1); Ramesh Srinivasan assumed EVP and Chief Strategy Officer role.
Item 2.02 verify on EDGAR →
Summary
McKesson reported strong first-quarter fiscal 2027 results and raised its full-year outlook, signaling confidence in its core pharmaceutical distribution and oncology businesses. Adjusted earnings per share grew 20% to $9.93, driven by increased prescription volumes, specialty product distribution, and a lower share count following aggressive buybacks.
The company lifted its full-year adjusted EPS guidance to $44.20–$45.00, up from $43.80–$44.60, implying double-digit growth. The Board approved a 15% dividend increase to $0.94 per share, the tenth consecutive annual raise, and the company returned $2.6 billion to shareholders in the quarter through $2.5 billion in repurchases and $102 million in dividends.
McKesson also advanced its planned separation of the Medical-Surgical Solutions segment, selling a 13% stake to Apollo for $1.25 billion, securing a $2.25 billion Term Loan B facility, and unveiling Wellverse as the future standalone business name. These steps indicate material progress toward completing the transaction. GAAP EPS declined year-over-year to $5.15 due to a $293 million redemption value adjustment tied to redeemable noncontrolling interests in the Medical-Surgical segment, a non-cash accounting item related to the separation. For retail holders, the raised guidance, dividend growth, and substantial capital return underscore McKesson's operational momentum and disciplined capital allocation.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
McKesson reported preliminary Q1 FY2027 results for the quarter ended June 30, 2026.
Added in current filing · verify on EDGAR →
On August 5, 2026, McKesson Corporation (the “Company”) reported the Company’s preliminary results for the quarter ended on June 30, 2026 which are attached hereto as Exhibit 99.1.
McKesson disclosed preliminary financial results for its first fiscal quarter ended June 30, 2026. The detailed results are contained in Exhibit 99.1, which is furnished but not filed with the SEC. This is a routine quarterly earnings announcement.
Event · Exhibit 99.1
Added in current filing · view on EDGAR → · paraphrased
Consolidated revenues of $105.4 billion increased 8%. Earnings per diluted share of $5.15 decreased $1.10. Adjusted Earnings per Diluted Share of $9.93 increased 20%. Raised Adjusted Earnings per Diluted Share guidance range to $44.20 to $45.00, from the previous range of $43.80 to $44.60. Fiscal 2027 Adjusted Earnings per Diluted Share guidance range indicates 13% to 15% growth compared to the prior year.
McKesson reported first quarter fiscal 2027 revenues of $105.4 billion, up 8% year-over-year, driven by increased prescription volumes and specialty product distribution. GAAP diluted EPS fell to $5.15 from $6.25 a year ago, primarily due to a $293 million redemption value adjustment related to redeemable noncontrolling interests in the Medical-Surgical Solutions segment. However, adjusted EPS rose 20% to $9.93, reflecting strong operational growth in North American Pharmaceutical and Oncology & Multispecialty segments and a lower share count. The company raised its full-year adjusted EPS guidance to $44.20–$45.00 from $43.80–$44.60, implying 13%–15% growth versus the prior year.
Added in current filing · view on EDGAR →
McKesson returned $2.6 billion to shareholders, including $2.25 billion through the May 2026 accelerated share repurchase program. ... Additionally, McKesson returned $2.6 billion of cash to shareholders, which included $2.5 billion of common stock repurchases and $102 million of dividend payments. ... In the quarter, McKesson completed $2.5 billion share repurchases, including $2.25 billion under the accelerated share repurchase program.
During the first quarter, McKesson returned $2.6 billion to shareholders, comprising $2.5 billion in share repurchases (including a $2.25 billion accelerated share repurchase program completed in May 2026) and $102 million in dividend payments. This substantial capital return reflects the company's disciplined capital allocation framework and strong cash generation.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 6, 2026 · How we verify